Alta Advisers Ltd Has $407,000 Stake in Stryker Co. (NYSE:SYK)

Alta Advisers Ltd boosted its position in Stryker Co. (NYSE:SYK) by 25.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,131 shares of the medical technology company’s stock after buying an additional 231 shares during the period. Alta Advisers Ltd’s holdings in Stryker were worth $407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Morse Asset Management Inc raised its stake in Stryker by 16.5% in the 3rd quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company’s stock worth $509,000 after purchasing an additional 200 shares in the last quarter. World Investment Advisors LLC raised its position in shares of Stryker by 126.1% in the third quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company’s stock valued at $2,941,000 after buying an additional 4,541 shares in the last quarter. Arvest Bank Trust Division acquired a new stake in Stryker during the third quarter worth approximately $245,000. Wilmington Savings Fund Society FSB grew its position in Stryker by 13.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 44,795 shares of the medical technology company’s stock worth $16,183,000 after buying an additional 5,361 shares in the last quarter. Finally, Tidal Investments LLC raised its holdings in Stryker by 13.9% in the 3rd quarter. Tidal Investments LLC now owns 17,478 shares of the medical technology company’s stock valued at $6,314,000 after acquiring an additional 2,139 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SYK has been the topic of several analyst reports. Canaccord Genuity Group increased their target price on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. BTIG Research set a $403.00 target price on shares of Stryker and gave the company a “buy” rating in a report on Monday, April 14th. Argus set a $450.00 target price on shares of Stryker in a research report on Monday, February 3rd. Citigroup reiterated a “buy” rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Finally, Barclays upped their target price on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $423.53.

Stryker Stock Down 1.9 %

Shares of NYSE:SYK opened at $339.96 on Tuesday. The business has a fifty day simple moving average of $370.04 and a 200 day simple moving average of $373.23. The firm has a market cap of $129.76 billion, a P/E ratio of 43.81, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm posted $3.46 earnings per share. Analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.99%. Stryker’s dividend payout ratio is presently 43.30%.

Insider Buying and Selling

In other news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.